Tetrazolyl-substituted quinuclidines as substance P antagonists

Details Tetrazolyl-substituted quinuclidines as substance P antagonists Tetrazolyl-substituted quinuclidines as substance P antagonists

1997-09-05

1999-08-17

Shah, Mukund J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

546133, 546137, A61K 3144, C07D45302

Patent

active

059394340

ABSTRACT:
This invention provides a compound of the formula: ##STR1## and its pharmaceutically acceptable salts, wherein R.sup.1 is halo, C.sub.1 -C.sub.6 alkyl, halo C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy or halo C.sub.1 -C.sub.6 alkoxy; R.sup.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, halo C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkyl-S-, C.sub.1 -C.sub.6 alkyl-SO--, C.sub.1 -C.sub.6 alkyl-SO.sub.2 --, cyclopropyl, phenyl, --NH.sub.2, --NH(CH.sub.3), --NHC(.dbd.O)CH.sub.3, --N(CH.sub.3).sub.2, --N(C.sub.2 H.sub.5).sub.2 or --CH.sub.2 C(.dbd.O)CF.sub.3 ; Ar.sup.1 and Ar.sup.2 are independently phenyl, halophenyl or thienyl; X is NH, O or S; and Y is hydrogen, --COOR.sup.3 or --CONR.sup.4 R.sup.5, wherein R.sup.3, R.sup.4 and R.sup.5 are independently hydrogen or C.sub.1 -C.sub.6 alkyl. These compounds are useful as analgesics or anti-inflammatory agents, or in the treatment of allergic disorders, angiogenesis, CNS disorders, emesis, gastrointestinal disorders, sunburn, urinary incontinence, or diseases, disorders or adverse conditions caused by Helicobacter pylori, or the like, in a mammalian subject, especially human, especially as analgesics or anti-inflammatory agents in the periphery.

REFERENCES:
patent: 4680283 (1987-07-01), Veber et al.
patent: 5242930 (1993-09-01), Baker et al.
patent: 5288730 (1994-02-01), Baker et al.
patent: 5538982 (1996-07-01), Hagen et al.
patent: 5569662 (1996-10-01), Satake et al.
patent: 5604241 (1997-02-01), Ito et al.
patent: 5716965 (1998-02-01), Ito et al.
patent: 5741797 (1998-04-01), Satake
C.J. Swain et al., in the Journal of Medicinal Chemistry, vol. 38,. No. 24, pp. 4793-4805 (1995).
P. Ward et al., in the Journal of Medicinal Chemistry, vol. 38, No. 26, pp. 4985-4992 (1995).
E.J. Warawa et al., in the Journal of Medicinal Chemistry, vol. 17, No. 5, p. 497 (1974).
S. R. Wilson et al., in the Journal of the American Chemical Society, vol. 102, No. 10, p. 3577 (1980).
D. G. Payan et al., in the Journal of Immunology, vol. 133, p. 3260 (1984).
I. J. Reynolds et al., in the Journal of Pharmacology and Experimental Therapeutics, vol. 237, p. 731 (1986).
A. Nagahisa et al., in the European Journal of Pharmacology, vol. 217, pp. 191-195 (1992).
C.J. Swain et al., in the Bioorganic and Chemistry Letters, vol. 3, No. 8, pp. 1703-1706, (1993).
D.R. Armour et al., in Bioorganic and Medicinal Chemistry Letters, vol. 6, No. 9, pp. 1015-1020 (1996).
C.C. Eschenfelder et al., in the European Journal of Neuroscience, vol. 7, pp. 1520-1526 (1995).

Affiliated with

Also associated with

Rating

Tetrazolyl-substituted quinuclidines as substance P antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tetrazolyl-substituted quinuclidines as substance P antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrazolyl-substituted quinuclidines as substance P antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-315046